Printer Friendly Version  View printer-friendly version
<< Back
Array BioPharma Announces Clinical Data Presentations At The 2015 European Cancer Congress

BOULDER, Colo., Sept. 11, 2015 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced presentations on encorafenib and binimetinib at the 2015 European Cancer Congress (ECC), which will be held September 25 - 29, 2015 in Vienna, Austria.  These products are currently advancing in a total of three pivotal trials, with top-line results expected over the next year from the NEMO (binimetinib monotherapy in NRAS mutant melanoma) and COLUMBUS (binimetinib and encorafenib in BRAF mutant melanoma) Phase 3 trials.

Array BioPharma

Ron Squarer, Chief Executive Officer of Array, noted, "We are encouraged to see two ECC abstracts reporting clinical data from binimetinib and encorafenib.  Importantly, the LOGIC2 presentation at ECC will provide a further opportunity to demonstrate the safety and clinical activity profile of this combination in a larger, independent data set."

The following is a summary of the presentations that will be given at ECC. 



 A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma naive to BRAFi treatment (Abstract #3300)


Carla van Herpen, MD


Monday, September 28, 9 – 9:15 a.m. CEST (Oral Presentation)

Updated data will be provided at the conference, beyond what is included in the abstract.



LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma (Abstract #3310)


Reinhard Dummer, MD


Sunday, September 27, 4:45 - 6:45 p.m. CEST

Abstract #3310 will also be included in the Poster Spotlight Session on Sunday, September 27, 5:15 - 6:15 p.m.

Updated data will be provided at the conference, beyond what is included in the abstract.

All abstracts can be accessed through the ECC website,

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Six registration studies are currently advancing related to three cancer drugs. These programs include binimetinib (MEK162 / wholly-owned), encorafenib (LGX818 / wholly-owned) and selumetinib (AstraZeneca). For more information on Array, please go to


 Tricia Haugeto

(303) 386-1193

Logo -


To view the original version on PR Newswire, visit:

SOURCE Array BioPharma

ShareThis Copy and Paste